Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma

BACKGROUND: Preclinical and translational evidence suggest BRAF/MEK inhibitors modulate the tumor microenvironment (TME), providing rationale for combination with immunotherapy. METHODS: This investigator-initiated, phase I trial evaluated pembrolizumab, vemurafenib, and cobimetinib in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaikh, Saba S., Zang, Yan, Hanmer, Janel, Wang, Hong, Lin, Yan, Davar, Diwakar, Zarour, Hassane M., Kirkwood, John M., Najjar, Yana G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727229/
https://www.ncbi.nlm.nih.gov/pubmed/36505793
http://dx.doi.org/10.3389/fonc.2022.1022496

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727229/
https://www.ncbi.nlm.nih.gov/pubmed/36505793
http://dx.doi.org/10.3389/fonc.2022.1022496

Ejemplares similares